Historical Grant

PAR-25-051: Blueprint Neurotherapeutics Network (BPN) Small-Molecule Drug Discovery (UG3/UH3)

NIH’s PAR-25-051 NOFO supported small-molecule neuroscience drug discovery and development through UG3/UH3 cooperative agreements, with NIH consultants and contract research organizations available for selected development work. The final listed application deadline has passed, so this page is a historical reference.

FindMyMoney.App
Published by FindMyMoney.App
Official source: National Institutes of Health
💰 Funding Application budgets were not limited, but had to reflect the actual needs of the proposed …
đź“… Deadline Historical reference
📍 Location United States and International (non-U.S. organizations eligible)
🏛️ Source National Institutes of Health

PAR-25-051: Blueprint Neurotherapeutics Network (BPN) Small-Molecule Drug Discovery (UG3/UH3)

Key Details
Funding opportunityPAR-25-051
Official titleBlueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
Program statusHistorical reference; the final listed application deadline has passed
Final listed application deadline2026-07-15, by 5:00 PM local time of the applicant organization
NOFO expiration date2026-08-19
Funding instrumentUG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement
Clinical trialsOptional; applications may propose a clinical trial or may not
Award budgetNo stated limit; the budget must reflect the actual needs of the proposed project
Award periodUp to 1 year of UG3 and up to 4 years of UH3, with a total project period not exceeding 5 years
Submission routes in the closed cycleNIH ASSIST, institutional system-to-system submission, or Grants.gov Workspace, followed by eRA Commons tracking

Status of this opportunity

This page is a historical reference for the closed PAR-25-051 cycle. NIH lists July 15, 2026 as the final scheduled due date for new applications and allowed resubmission or revision applications. The NOFO expired on August 19, 2026; that was the notice expiration date, not an additional application deadline. The official NIH Guide search for this refresh did not identify a later small-molecule UG3/UH3 BPN notice, so no new cycle deadline is available to report. NIH notes that limited late or continuous-submission cases can be considered individually after an NOFO expires; that exception is not an open application window for this program. Applicants with a submission issue should follow NIH guidance and contact the eRA Service Desk. Researchers should not treat this archive entry as an invitation to submit a new application.

The official source remains the NIH Guide notice at the URL in the front matter. A local HTTP request returned 403, but the official NIH Guide page and its full PAR-25-051 text were available in NIH-indexed content for this review. The URL is the authoritative notice and remains unchanged; the status metadata records both the local access response and how the official text was verified.

What the BPN was designed to support

The Blueprint Neurotherapeutics Network (BPN) invited neuroscience investigators to advance small-molecule drug discovery and development projects toward the clinic. The program was not a general-purpose mechanism for disease biology or an unrestricted compound-screening project. Its center of gravity was the difficult translational work between a credible chemical starting point and a development candidate that can proceed through preclinical safety work and, where appropriate, Phase I testing.

The notice describes two entry paths. A project could enter at a Discovery stage such as exploratory work, hit-to-lead, or lead optimization. In that path, the team would characterize and optimize promising hits, establish structure-activity and structure-property relationships, and develop evidence about properties such as metabolism, selectivity, and toxicity. A project could also enter at a Development stage when it already had a sufficiently profiled candidate and needed to progress toward IND-enabling toxicology and Phase I clinical testing.

The small-molecule boundary matters. The notice is intended for compounds that can be readily synthesized and chemically modified if optimization is required. It is not designed for biologics or biotechnology products such as proteins and oligonucleotides, or for devices. The notice also identifies activities that are nonresponsive, including screening solely to identify hit compounds, basic research and disease-mechanism studies, animal-model development, diagnostic or biomarker development, development of biologics, and studies directed beyond Phase I clinical testing.

The disease focus must fit the mission of at least one participating NIH Institute or Center. Participating components listed in the notice include NINDS, NEI, NIA, NIAAA, NIDCR, NIDA, NIMH, and NCCIH. Program fit is therefore both technical and institutional: a strong compound-development plan still needs a nervous-system indication that matches the mission and priorities of a participating component.

Funding and project structure

PAR-25-051 uses an UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement. The notice does not set a numeric award ceiling. Instead, it says application budgets are not limited but must reflect the actual needs of the proposed project. A realistic budget still needs to match the work the applicant will perform, the proposed period of support, and the stage-specific plan. “No stated limit” should not be read as permission to submit an unsupported or inflated request.

Applicants could seek up to one year of UG3 funding. The UH3 phase could not exceed four years, and the total project period could not exceed five years. The actual duration depended on successful achievement of milestones and the conditions described in the program overview. The transition from UG3 to UH3 was not automatic. The program established go/no-go milestones, typically every six months but at least annually, and NIH program staff with technical input from an External Oversight Committee evaluated whether a project should advance.

The continuation decision considered successful milestone achievement, the overall feasibility of further advancement, the competitive situation for the disease indication and target, program priorities, and availability of funds. If a funded project failed to make sufficient progress toward agreed milestones, funding and access to BPN contract resources could be discontinued. A proposal therefore needed more than a promising target: it needed measurable decision points, evidence appropriate to its entry stage, and a credible plan for handling failed experiments or a change in development direction.

The cooperative-agreement model also creates meaningful NIH involvement after award. NIH assembles a customized Lead Development Team, normally co-chaired by the PI and an NIH-contracted drug-development consultant, with members from the applicant team, additional consultants, and NIH staff. The team helps establish strategy, propose milestones, coordinate contractor work, and interpret results. If the project reaches clinical development, the Lead Development Team is replaced by a Clinical Development Team that includes the PI, clinical consultants, and NIH staff.

What support could be coordinated through BPN

The applicant remained responsible for studies involving disease- or target-specific assays, models, and research tools in the applicant’s own laboratory. Depending on the team’s expertise and resources, the application could request support for additional work in the applicant’s laboratory, while collaborating with BPN contractors for specialized activities. The notice names medicinal chemistry, pharmacokinetics, toxicology, formulation development, chemical synthesis under current Good Manufacturing Practice, and Phase I clinical testing among the areas that contractors and consultants may support.

This arrangement was intended to accommodate different starting points. A team with strong medicinal chemistry capacity could retain more chemistry work and seek support for ADMET, in vivo pharmacokinetics, manufacturing, or IND-enabling toxicology. A team with limited drug-development infrastructure could propose to use more of the available contractor network. Applicants were expected to explain what their own group would do, what collaborators would do, and where NIH-provided resources would be needed.

The program’s intellectual-property structure was another important planning issue. The recipient institution retains its assignment of IP rights and gains assignment of IP rights from BPN contractors and consultants for drug candidates developed through the program. The institution is expected to take responsibility for patent filings, maintenance, licensing, and commercialization planning. Academic applicants needed to involve the technology-transfer or business-development office early enough to address existing rights, prior art, licensing constraints, and any arrangements among multiple institutions.

Eligibility and registrations

The official eligibility list is broad. It includes public and private higher education institutions; nonprofit organizations; small businesses and other for-profit organizations; state, county, city, special-district, and tribal governments; eligible federal agencies; U.S. territories or possessions; independent school districts; public or Indian housing authorities; tribal organizations; faith-based or community-based organizations; regional organizations; and non-domestic entities. Foreign organizations and non-domestic components of U.S. organizations are eligible to apply, subject to the applicable NIH policies.

Eligibility also depends on administrative readiness. Applicant organizations must complete and maintain the registrations described in the NIH How to Apply - Application Guide before submitting. The notice specifically points applicants to the unique entity identifier, System for Award Management, eRA Commons, and Grants.gov requirements. Registration can take six weeks or more, and an incomplete registration is not a valid reason for a late submission. Each PD/PI must include a valid eRA Commons ID in the Credential field of the Senior/Key Person Profile form, and the UEI in the application must match the identifier used in the organization’s eRA Commons and SAM profiles.

The allowed application types are New, Resubmission, and Revision. Renewal applications are not listed as an allowed type in the notice. Applicants also needed to make sure the proposed condition fit a participating Institute or Center and that the work was responsive to the small-molecule drug-discovery scope. A project that primarily develops a biologic, a device, a diagnostic, or a disease model would need a different NIH opportunity.

Application route and materials

The notice offered three ways to prepare and submit an application: NIH ASSIST; an institutional system-to-system solution that submits to Grants.gov and uses eRA Commons for tracking; or Grants.gov Workspace with eRA Commons tracking. Paper applications were not accepted. After submission, the organization was responsible for tracking the application in eRA Commons, viewing it before the deadline, and correcting any errors by submitting a changed or corrected application to Grants.gov on or before the due date and time. A corrected application submitted after the deadline could be considered late.

Applicants had to follow the Research instructions in the NIH How to Apply - Application Guide, together with the program-specific instructions in PAR-25-051. The core Research Strategy needed to make the entry stage clear, establish the biological rationale and supporting evidence, describe the compound and its disease relevance, and define milestones that can support a go/no-go decision. The application also needed to distinguish work performed by the applicant from work that could be performed by BPN contractors.

The notice adds several materials that are especially relevant to this program. Academic applicants had to include a letter of support from the technology-transfer official responsible for IP and licensing, with agreement to share licensing details confidentially with NIH when relevant to commercialization feasibility. If work would take place at more than one institution, each institution had to provide a letter explaining how IP would be shared or managed without encumbering the program goals. The application also required an IP strategy and a description of the institution’s ability to manage and commercialize the candidate. Applications generating scientific data had to address the Data Management and Sharing Plan, regardless of the direct-cost request for a year. Only limited Appendix materials were allowed; publications and other material could not be added there, except blank questionnaires or blank surveys.

When human subjects research or a clinical trial is proposed, the application must include the required PHS Human Subjects and Clinical Trials Information forms. The notice calls for attention to dose levels, route of administration, and pharmacokinetic outcome measures, including CNS penetration and target engagement or modulation when appropriate. Clinical-trial plans should be proportionate to the stage: BPN supports up to Phase I, primarily human pharmacokinetics and tolerability, and the applicant is not expected to provide a Phase II design in this application.

How a strong application would have been prepared

The first planning question was stage fit. A Discovery-stage proposal needed a credible hit or lead, assay evidence relevant to the proposed indication, and a plan to establish the data needed for optimization. A Development-stage proposal needed a well-profiled and optimized candidate with in vitro and in vivo activity and ADMET properties appropriate to the intended clinical use. The proposal should explain why the intended route and exposure are plausible and how the candidate could reach IND-enabling work.

The second question was division of labor. Reviewers considered whether the PI team had the expertise and resources for the work it proposed to conduct itself and whether the PI could lead the collaboration with NIH staff and BPN consultants. It was reasonable to suggest contractors or consultants where specialized expertise was needed, but the applicant still had to own the disease-specific science, the key assays and models, the interpretation of results, and the milestone plan.

The third question was quality and compliance. IND-enabling nonclinical studies are expected to follow Good Laboratory Practice and applicable FDA guidance. Clinical trials must follow Good Clinical Practice and NIH data-and-safety-monitoring policy. Investigational products for clinical trials must be produced under current Good Manufacturing Practice. These are not post-award details to be left out of the proposal; they affect the schedule, facilities, contractor plan, and budget.

Finally, the application needed an IP and commercialization plan that was credible for the proposed chemical scaffold and disease indication. Reviewers considered prior-art or licensing constraints, the ability to develop and commercialize the candidate, and the management of IP across institutions. The notice also asks reviewers to consider biological rationale, drug-like properties, potential patient benefit, novelty, study rigor, and the likelihood of a path into the clinic.

Historical-reference guidance

PAR-25-051 is closed. Its final scheduled application date was July 15, 2026, and the NOFO expired on August 19, 2026. The expiration date did not create a later submission window. NIH states that a limited late or continuous-submission exception may be considered case by case after expiration, but that policy does not make this closed funding opportunity generally available. The official NIH Guide search for this refresh found no later small-molecule UG3/UH3 BPN announcement. Researchers interested in a future round should look for a separately published NIH notice and use that notice’s deadline and instructions.

The official NOFO remains useful for understanding the BPN model: small-molecule projects can enter at Discovery or Development, NIH can coordinate specialized contractor support, the award uses UG3 and UH3 phases, and continuation depends on milestones and program review. Those facts describe the published PAR-25-051 mechanism. They do not make the closed cycle available for a new submission.

Official source

Use the official NIH notice for any future replacement announcement, updated application instructions, or Institute-specific contact guidance.

Next step
Check official source